

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/712,391	ATTY. DOCKET NO.: B0801.70256US01
				FILING DATE: November 12, 2003	CONFIRMATION NO.: 8225
				APPLICANT: Pier et al.	
				GROUP ART UNIT: 1652	EXAMINER: Christian L. Fronda
Sheet	1	of	2		

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		4,465,776		Pier et al.	08-14-1984
		7,157,443	B2	Joyce et al.	01-02-2007

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		New York Times, Editorial, Another Very Scary Germ. November 20, 2007. Accessed April 22, 2009. < http://www.nytimes.com/2007/11/20/opinion/20tue2.html?_r=2&oref=slogin&pagewanted...> 2 pages.	
		CERCA et al., Comparative antibody-mediated phagocytosis of <i>Staphylococcus epidermidis</i> cells grown in a biofilm or in the planktonic state. <i>Infect Immun.</i> 2006 Aug;74(8):4849-55.	
		CERCA et al., Influence of batch or fed-batch growth on <i>Staphylococcus epidermidis</i> biofilm formation. <i>Lett Appl Microbiol.</i> 2004;39(5):420-4.	
		CERCA et al., Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine. <i>Infect Immun.</i> 2007 Jul;75(7):3406-13. Epub 2007 Apr 30.	
		CERCA et al., Protection against <i>Escherichia coli</i> infection by antibody to the <i>Staphylococcus aureus</i> poly-N-acetylglucosamine surface polysaccharide. <i>Proc Natl Acad Sci U S A.</i> 2007 May 1;104(18):7528-33. Epub 2007 Apr 19.	
		HUANG et al., Risk of methicillin-resistant <i>Staphylococcus aureus</i> infection after previous infection or colonization. <i>Clin Infect Dis.</i> 2003 Feb 1;36(3):281-5. Epub 2003 Jan 17.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/712,391	ATTY. DOCKET NO.: B0801.70256US01
				FILING DATE: November 12, 2003	CONFIRMATION NO.: 8225
				APPLICANT: Pier et al.	
				GROUP ART UNIT: 1652	EXAMINER: Christian L. Fronda
Sheet	2	of	2		

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		KELLY-QUINTOS et al., The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine. <i>J Infect Dis.</i> 2005 Dec 1;192(11):2012-9. <i>Epub</i> 2005 Nov 1.	
		KLEVENS et al., Invasive methicillin-resistant <i>Staphylococcus aureus</i> infections in the United States. <i>JAMA.</i> 2007 Oct 17;298(15):1763-71.	
		KROPEC et al., Poly-N-acetylglucosamine production in <i>Staphylococcus aureus</i> is essential for virulence in murine models of systemic infection. <i>Infect Immun.</i> 2005 Oct;73(10):6868-76.	
		KUEHNERT et al., Methicillin-resistant- <i>Staphylococcus aureus</i> hospitalizations, United States. <i>Emerg Infect Dis.</i> 2005 Jun;11(6):868-72. Erratum in: <i>Emerg Infect Dis.</i> 2006 Sep;12(9):1472.	
		MAIRA-LITRAN et al., Comparative opsonic and protective activities of <i>Staphylococcus aureus</i> conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine. <i>Infect Immun.</i> 2005 Oct;73(10):6752-62. Erratum in: <i>Infect Immun.</i> 2005 Nov;73(11):7789.	
		SACK, Deadly Bacteria Found to Be More Common. <i>New York Times.</i> October 17, 2007. Accessed April 22, 2009. < http://www.nytimes.com/2007/10/17/health/17infect.html?pagewanted=print > 3 pages.	
		ZELLER et al., JAMA patient page. MRSA infections. <i>JAMA.</i> 2007 Oct 17;298(15):1826.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

[#] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.